A Research Study to Investigate How Well NNC0165-1875 in Combination With Semaglutide Works in People With Obesity

NCT04969939 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

Obesity

Interventions

DRUG: Semaglutide 2.4 mg and NNC0165-1875 2.0 mg
DRUG: Semaglutide 2.4 mg and placebo 2.0 mg
DRUG: Semaglutide 2.4 mg and NNC0165-1875 1.0 mg
DRUG: Semaglutide 2.4 mg and placebo 1.0 mg

Sponsor

Novo Nordisk A/S